获取途径

作者

Shulai Zhu, Weiwei Pan, Yingjie Yao, Kai Shi

作者单位

Affiliations ¹ Department of Neurology, The Second People's Hospital of Liaocheng, The Second Hospital of Liaocheng Affiliated to Shandong First Medical University, No.306, Jiankang Street, Linqing, 252600, China. ² Department of Cadre Health Care, Qingdao Municipal Hospital, No.1, Jiaozhou road, Qingdao, 266011, China. ³ Department of Cardiology, Qingdao Hiser Hospital Affiliated of Qingdao University (Qingdao Traditional Chinese Medicine Hospital) No.4, Qingdao Renmin Road, 266000, China.

刊名

Scandinavian cardiovascular journal : SCJ

年份

2024

页码

1-11

ISSN

1651-2006

关键词

Cardiovascular Colchicine Meta-analysis Prevention Stroke.

摘要

Background: Colchicine is an anti-inflammatory drug with promising efficacy for preventing cardiovascular events. We aimed to assess the pooled effect of colchicine on ischemic stroke among patients with established atherosclerotic cardiovascular diseases. Methods: PubMed, Scopus, Web of Science, and the Cochrane Library were systematically searched from the inception to August 5, 2024. A random-effects model was used to conduct this meta-analysis. The inclusion criteria were as follows: being...更多

Background: Colchicine is an anti-inflammatory drug with promising efficacy for preventing cardiovascular events. We aimed to assess the pooled effect of colchicine on ischemic stroke among patients with established atherosclerotic cardiovascular diseases. Methods: PubMed, Scopus, Web of Science, and the Cochrane Library were systematically searched from the inception to August 5, 2024. A random-effects model was used to conduct this meta-analysis. The inclusion criteria were as follows: being a randomized controlled trial; and measuring the efficacy of colchicine compared to placebo for preventing ischemic stroke among those with established atherosclerotic cardiovascular diseases. Results: We identified 13 eligible clinical trials with 24900 participants. Colchicine significantly decreased the risk of ischemic stroke 0.85, 95% confidence interval , I=2.92%) among those with established atherosclerotic cardiovascular diseases. Colchicine was more effective when used at 0.5 mg/day ), prescribed for more than 30 days ) or for more than 90 days ), or administered for patients with acute coronary syndrome ). In addition, colchicine was more effective in studies with a sample size of more than 500 patients, consistent with sensitivity analysis, which indicated that the results relied on large-sized clinical trials. Conclusion: Colchicine may decrease the risk of ischemic stroke among patients with established atherosclerotic cardiovascular diseases, particularly after long-term use; however, future studies are needed due to inconsistencies between existing trials.收起

文献类型

期刊

浏览量

2